Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis

Status:
Terminated

Trial end date:
2014-04-01

Target enrollment:

Participant gender:

To evaluate the efficacy and safety of AIN457 versus placebo in patients with relapsing multiple sclerosis.

Phase 2

Novartis Pharmaceuticals